Ignite Creation Date:
2024-05-06 @ 2:34 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02076646
Status:
UNKNOWN
Last Update Posted:
2022-04-14
First Post:
2014-02-24
Brief Title:
A Phase III Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Sponsor:
Philogen SpA
Organization:
Philogen SpA